No Data
No Data
Express News | Honz Pharmaceutical: Proposing to the shareholder meeting to authorize the board of directors to issue stocks to specific objects by simplified procedure.
Kangzhi Pharmaceutical responded to the annual report inquiry letter: Hongshi Investment stated that it has sufficient ability to fulfill repurchase obligations
On the evening of May 28, Kangzhi Pharmaceutical responded to the annual report inquiry letter. Due to the wholly-owned subsidiary Zhongshan Care's cumulative net profit for the five fiscal years 2018-2023 of -989.645 million yuan, less than 50% of the promised amount of 172.156 million yuan. According to the terms of the relevant agreement, Hongshi Investment has now reached the obligation to repurchase 100% of Zhongshan Aihua's shares. In response to the annual report inquiry letter, Hongshi Investment stated that it is disposing of the relevant assets and raising funds as soon as possible to fulfill the repurchase obligation. According to the relevant agreement signed with Hongshi Investment, since Zhongshan Care did not complete the performance assessment, Hongshi Investment needed to buy back Zhongshan Ai
Changes in the A-share baby concept boosted Dajia Weikang by more than 10%
Glonghui, May 9 | Dajia Weikang surged more than 10%, followed by Kangzhi Pharmaceutical, Lanwei Medical, Yuexin Health, Jinrabi, and Xinguang Pharmaceutical. According to the news, the National Health and Health Commission will hold a press conference at 15:00 on May 9 to introduce the “Implementing the Requirements for High-Quality Population Development and Actively Establishing a Fertility Support Policy System”.
Kangzhi Pharmaceutical (300086.SZ) announced first-quarter results, with a net loss of 46.5 million yuan, which changed from profit to loss over the previous year
Kangzhi Pharmaceutical (300086.SZ) disclosed its report for the first quarter of 2024. The company achieved revenue of 1.0 during the reporting period...
Kangzhi Pharmaceutical (300086.SZ): Currently mainly selling children's medicines include pediatric antipyretic patches, pediatric detoxifying granules, etc.
Gelonghui, March 8 | Kangzhi Pharmaceutical (300086.SZ) recently said during a survey of institutional investors that the company currently mainly sells levocetirizine hydrochloride granules (exclusive dosage form), ibuprofen granules, pediatric antipyretic patches, pediatric antipyretic granules, ammoniacin granules, aminophen yellow nanamine granules, yinhu cold powder, montmorillonite powder, tannic acid protein yeast powder, lactic acid bacterin granules, gastrointestinal dispersion, Zierling granules, Jianlemeng granules Decalcification powder, cough relief orange red granules, carboxymethane granules, pediatric phlegm granules, pediatric phlegm relief granules, head faclor granules, ribavirin
Kangzhi Pharmaceutical (300086.SZ): Injectable sulamine sodium is a product the company is developing and has not yet been marketed for sale
Gelonghui, January 12 | Kangzhi Pharmaceutical (300086.SZ) said on the investor interactive platform that injectable sulamine sodium is a product the company is developing and has not yet been marketed for sale. At that time, the research report on the “Horizontal Research Project Research Cooperation Agreement” between the company and the Guangdong Provincial Institute of Public Health had already been released.
No Data